Pulmonary Hypertension Registry Mainz

Pulmonary Hypertension Registry Mainz - PHYREM

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00006245

Enrollment

300

Registered

2015-04-30

Start date

2016-12-14

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I27.2 I27.0

Interventions

Group 1: Patients with confirmed diagnosis of pulmonary hypertension will be followed every 6 months over a period of 3 years by documentation of clinical, imaging, and laboratory examination results.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) Confirmed diagnosis of pulmonary Hypertension and (2) written informed consent of study participants or their legal representative.

Exclusion criteria

Exclusion criteria: Anticipated non-compliance or inability to adhere to study protocol (deficient willingness or ability to cooperate).

Design outcomes

Primary

Measure	Time frame
This prospective non-interventional study aims to evaluate the diagnostic, prognostic, and therapeutic strategies as well as the clinical long-term course of patients with confirmed diagnosis of pulmonary hypertension.	—

Secondary

Measure	Time frame
(1) To determine the prognostic value of the following parameters at diagnosis in relation to the patients’ clinical long-term outcome: (a) clinical (symptoms, clinical signs, predisposing (history) criteria and comorbidities), (b) imaging (echocardiography, if indicated: V/Q lung scan, computed tomographic (CT) angiography, magnetic resonance tomographic (MRT) angiography, conventional selective pulmonary angiography), and (c) laboratory (biomarker tests); (2) to find out optimal „cut-off“-values of different biomarkers from the categories mentioned above and to develop novel algorithms for risk stratification; (3) to analyze the course of these parameters or biomarkers as indicators of the response to therapy; (4) to identify novel diagnostic and prognostic biomarkers (under development and resulting from translational CTH research) in different patient groups of PH; (5) to investigate the influence of established and new therapeutic substances/schemes, and/or surgical/interventional therapies, on the prognosis, the functional status, and life quality of patients and to gather the progresses related to PH management on the long-term outcome.	—

Measure

Time frame

(1) To determine the prognostic value of the following parameters at diagnosis in relation to the patients’ clinical long-term outcome: (a) clinical (symptoms, clinical signs, predisposing (history) criteria and comorbidities), (b) imaging (echocardiography, if indicated: V/Q lung scan, computed tomographic (CT) angiography, magnetic resonance tomographic (MRT) angiography, conventional selective pulmonary angiography), and (c) laboratory (biomarker tests); (2) to find out optimal „cut-off“-values of different biomarkers from the categories mentioned above and to develop novel algorithms for risk stratification; (3) to analyze the course of these parameters or biomarkers as indicators of the response to therapy; (4) to identify novel diagnostic and prognostic biomarkers (under development and resulting from translational CTH research) in different patient groups of PH; (5) to investigate the influence of established and new therapeutic substances/schemes, and/or surgical/interventional therapies, on the prognosis, the functional status, and life quality of patients and to gather the progresses related to PH management on the long-term outcome.

—

Countries

Germany

Contacts

Public ContactStavros Konstantinides

Universitätsmedizin der Johannes Gutenberg-Universität Mainz

stavros.konsantinides@unimedizin-mainz.de06131/17-8297

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026